Andreasen Camilla Helene, Mogensen Mette Sloth, Borch-Johnsen Knut, Sandbaek Annelli, Lauritzen Torsten, Almind Katrine, Hansen Lars, Jørgensen Torben, Pedersen Oluf, Hansen Torben
Steno Diabetes Center, Gentofte, Denmark.
BMC Med Genet. 2009 Feb 26;10:17. doi: 10.1186/1471-2350-10-17.
A genome-wide scan in unrelated US Caucasians identified rs7001819 upstream of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) and multiple variants within catenin (cadherin-associated protein), beta-like 1 (CTNNBL1) to associate strongly with body mass index (BMI). The most significantly associating variants within CTNNBL1 including rs6013029 and rs6020846 were additionally confirmed to associate with morbid obesity in a French Caucasian case-control sample. The aim of this study was to investigate the impact of these three variants on obesity, through analyses of obesity-related quantitative traits, and case-control studies in large study samples of Danes.
The FDFT1 rs7001819, CTNNBL1 rs6013029 and rs6020846 were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising 18,014 participants ascertained from; the population-based Inter99 cohort (n = 6,514), the ADDITION Denmark screening study cohort (n = 8,662), and a population-based sample (n = 680) and a type 2 diabetic patients group (n = 2,158) from Steno Diabetes Center.
Both CTNNBL1 variants associated with body weight and height with per allele effect sizes of 1.0 [0.3-0.8] kg and 0.6 [0.2-0.9] cm, respectively, for the rs6020846 G-allele. No association was observed with BMI and waist circumference. In case-control studies neither of the CTNNBL1 variants showed association with overweight, obesity or morbid obesity (rs6013029: Odds Ratio (OR)(overweight) = 1.02 [0.90-1.16], OR(obesity) = 1.09 [0.95-1.25], OR(morbidobesity) = 1.26 [0.91-1.74]; rs6020846: OR(overweight) = 1.05 [0.93-1.18], OR(obesity) = 1.13 [1.00-1.28], OR(morbidobesity) = 1.17 [0.86-1.61]). However, in meta-analyses of the present and the previous study, both the rs6013029 T-allele and the rs6020846 G-allele increased the risk of developing morbid obesity (rs6013029: OR(combined) = 1.36 [1.12-1.64], p = 0.002; rs6020846: OR(combined) = 1.26 [1.06-1.51], p = 0.01), and obesity (rs6013029: OR(combined) = 1.17 [1.04-1.31], p = 0.007; rs6020846: OR(combined) = 1.17 [1.05-1.30], p = 0.004). The FDFT1 rs7001819 C-allele showed no association with obesity-related quantitative measures or dichotomous measures of overweight, obesity and morbid obesity.
CTNNBL1 variants associated with body weight and height, and confer the risk of developing obesity in meta-analyses combining the present and a previous study. FDFT1 rs7001819 showed no association with obesity, neither when analysing quantitative traits nor when performing case-control studies of obesity.
在美国无关的白种人中进行的全基因组扫描发现,法尼基二磷酸法尼基转移酶1(FDFT1)上游的rs7001819以及连环蛋白(钙黏蛋白相关蛋白)β样1(CTNNBL1)内的多个变异与体重指数(BMI)密切相关。在一个法国白种人的病例对照样本中,CTNNBL1内最显著相关的变异,包括rs6013029和rs6020846,被进一步证实与病态肥胖相关。本研究的目的是通过对肥胖相关定量性状的分析以及在丹麦的大型研究样本中进行病例对照研究,来调查这三个变异对肥胖的影响。
使用TaqMan等位基因鉴别技术,对来自基于人群的Inter99队列(n = 6514)、丹麦ADDITION筛查研究队列(n = 8662)、一个基于人群的样本(n = 680)以及来自斯滕诺糖尿病中心的2型糖尿病患者组(n = 2158)的18014名参与者组成的联合研究样本,进行FDFT1 rs7001819、CTNNBL1 rs6013029和rs6020846的基因分型。
对于rs6020846的G等位基因,CTNNBL1的两个变异均与体重和身高相关,每个等位基因的效应大小分别为1.0 [0.3 - 0.8] kg和0.6 [0.2 - 0.9] cm。未观察到与BMI和腰围的关联。在病例对照研究中,CTNNBL1的两个变异均未显示与超重、肥胖或病态肥胖相关(rs6013029:优势比(OR)(超重) = 1.02 [0.90 - 1.16],OR(肥胖) = 1.09 [0.95 - 1.25],OR(病态肥胖) = 1.26 [0.91 - 1.74];rs6020846:OR(超重) = 1.05 [0.93 - 1.18],OR(肥胖) = 1.13 [1.00 - 1.28],OR(病态肥胖) = 1.17 [0.86 - 1.61])。然而,在本研究与先前研究的荟萃分析中,rs6013029的T等位基因和rs6020846的G等位基因均增加了患病态肥胖的风险(rs6013029:OR(合并) = 1.36 [1.12 - 1.64],p = 0.002;rs6020846:OR(合并) = 1.26 [1.06 - 1.51],p = 0.01),以及肥胖的风险(rs6013029:OR(合并) = 1.17 [1.04 - 1.31],p = 0.007;rs6020846:OR(合并) = 1.17 [1.05 - 1.30],p = 0.004)。FDFT1 rs7001819的C等位基因与肥胖相关定量指标或超重、肥胖和病态肥胖的二分指标均无关联。
CTNNBL1变异与体重和身高相关,并在本研究与先前研究的荟萃分析中增加了患肥胖症的风险。FDFT1 rs7001819在分析定量性状时以及在进行肥胖症病例对照研究时,均未显示与肥胖相关。